The regulation of miR-181c and its control over TGF-β intermediates and signaling molecules is yet to be investigated in the context of diabetes-impaired angiogenesis but may offer a novel treatment paradigm for vascular complications in diabetes (Figure 2). Here, TGFB1 is linked to diabetes mellitus.